CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
December 12, 2024 07:00 ET
|
CytoSorbents
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.
CytoSorbents Announces Rights Offering
December 09, 2024 07:00 ET
|
CytoSorbents
CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Participate in the Piper Sandler 36th Annual Healthcare Conference. Management holding one-on-one meetings with investors
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
November 11, 2024 07:30 ET
|
CytoSorbents; Converge Biotech
CytoSorbents and Converge Biotech Partner In India to Expand CytoSorb Blood Purification Availability to Treat Sepsis and Other Deadly Conditions
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
November 04, 2024 07:00 ET
|
CytoSorbents
CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
October 22, 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
October 17, 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Announce Q3 2024 Financial and Operating Results on November 7, 2024
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
October 01, 2024 07:00 ET
|
CytoSorbents
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
August 27, 2024 07:00 ET
|
CytoSorbents
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
August 13, 2024 16:19 ET
|
CytoSorbents
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by...